Stocks in Aggressive Mood: Buckeye Partners, L.P. (NYSE:BPL), AK Steel Holding Corporation (NYSE:AKS), Bristol-Myers Squibb Company (NYSE:BMY)

Buckeye Partners, L.P. (NYSE:BPL) released that Buckeye Pipe Line Co., L.P. signed a settlement resolving all complaints filed with FERC by Delta Air Lines, JetBlue Airways, United/Continental Air Lines, as well as US Airways/American Airlines challenging Buckeye Pipe Line’s rates for transportation of jet fuel from New Jersey to three New York City area airports. In deciding complaints, Buckeye Pipe Line has decided to cut jet fuel rates prospectively and make settlement payments to the Airlines to close pending litigation. Buckeye Partners said the prospective reduction in rates will not have a material impact on Buckeye’s operating results. Shares of Buckeye Partners, L.P. (NYSE:BPL) opened at $77.96 with 127.29 million outstanding shares and hit to its highest price of $79.14 during the day and finally closed at $78.67 by scoring 1.77%.

AK Steel Holding Corporation (NYSE:AKS) dropped over 7% in previous session as it reported that it anticipates to released a net loss of $0.37 to $0.42 per share for the Q2 of 2015. Analysts polled by Thomson Reuters anticipate the firm to report a loss of $0.27 a share for the Q2. The firm reported that its anticipated Q2 results continued to be negatively impacted by lower carbon steel prices due to the continued high level of what it believes are unfairly traded imports. The company noted that the decrease in average selling price is mainly a result of continued high levels of imports that have negatively affected selling prices in the carbon spot market. On the other consideration, AK Steel Holding Corporation (NYSE:AKS) begun last trade with a price of $4.60 and throughout the trading session climbed at $4.66. The day-trade ended with a decrease of -7.45% to close at $4.35.

Bristol-Myers Squibb Company (NYSE:BMY) declared on Friday that the European Commission has endorsed Opdivo, a PD-1 immune checkpoint inhibitor, for the treatment of proceed melanoma in adults, regardless of BRAF status. The endorsement permits for the marketing of Opdivo in all 28 member states of the European Union. It follows an accelerated assessment by the Committee for Medicinal Products for Human Use, or CHMP. Opdivo is the only PD-1 immune checkpoint inhibitor to receive an accelerated assessment in Europe, and is the first approval given by the European Commission for a PD-1 inhibitor in any cancer.Bristol-Myers Squibb Company (NYSE:BMY) stock hit highest price at $67.73, beginning with a price of $67.44 to close at 67.06 by a gain of 0.39% with a day range of $66.93-$67.73.